Literature DB >> 11106801

Role in tumorigenesis of silent mutations in the TP53 gene.

B S Strauss1.   

Abstract

Over 10,000 mutations in the TP53 suppressor gene have been recorded in the International Agency for Research on Cancer (IARC) tumor data base. About 4% of these mutations are silent. It is a question whether these mutations play a role in tumor development. In order to approach this question, we asked whether the reported silent mutations are randomly distributed throughout the TP53 gene. The p53 data base was searched exon by exon. From the frequency of codons with no silent mutations, the average number of silent mutations per codon for each exon was calculated using the Poisson distribution. The results indicate the distribution to be non-random. About one-third of all silent mutations occur in "hot-spots" and after subtraction of these hot-spots, the remaining silent mutations are randomly distributed. In addition, the percentage of silent mutations among the total in the silent mutation hot-spots is close to that expected for random mutation. We conclude that most of the silent mutations recorded in tumors play no role in tumor development and that the percentage of silent mutation is an indication of the amount of random mutation during tumorigenesis. Silent mutations occur to a significantly different extent in different tumor types. Tumors of the esophagus and colon have a low frequency of silent mutations, tumors of the prostate have a high frequency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106801     DOI: 10.1016/s0027-5107(00)00135-4

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

1.  Clusters of mutations from transient hypermutability.

Authors:  John W Drake; Anna Bebenek; Grace E Kissling; Shyamal Peddada
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

2.  Mutation patterns in cancer genomes.

Authors:  Alan F Rubin; Phil Green
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

Review 3.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

4.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

5.  Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.

Authors:  Zhenbin Chen; Jinong Feng; Carolyn H Buzin; Steve S Sommer
Journal:  PLoS One       Date:  2008-11-13       Impact factor: 3.240

6.  High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer.

Authors:  Vladimir I Kashuba; Tatiana V Pavlova; Elvira V Grigorieva; Alexey Kutsenko; Surya Pavan Yenamandra; Jingfeng Li; Fuli Wang; Alexei I Protopopov; Veronika I Zabarovska; Vera Senchenko; Klas Haraldson; Tatiana Eshchenko; Julia Kobliakova; Olga Vorontsova; Igor Kuzmin; Eleonora Braga; Vladimir M Blinov; Lev L Kisselev; Yi-Xin Zeng; Ingemar Ernberg; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

7.  Network-based stratification of tumor mutations.

Authors:  Matan Hofree; John P Shen; Hannah Carter; Andrew Gross; Trey Ideker
Journal:  Nat Methods       Date:  2013-09-15       Impact factor: 28.547

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.